TY - JOUR
T1 - Safety and complications of central venous catheters in AIDS patients
AU - Consten, E. C.J.
AU - Van Lanschot, J. J.B.
AU - Movig, F. M.
AU - Rijsman, L.
AU - Oosting, J.
AU - Danner, S. A.
PY - 1998/9
Y1 - 1998/9
N2 - Objective: To investigate and compare the incidence and type of complications related to central venous catheters in AIDS patients and in two control groups of non-AIDS patients. Methods: Three groups of patients requiring permanent venous access were investigated retrospectively between January 1988 and January 1994, The indication for Port-A-Cath system implantation in AIDS patients was administration of virustatics and/or total parenteral nutrition (TPN) (group A, n = 71), in non-AIDS immunocompromised patients it was chemotherapy (group B, n = 65) and in immunocompetent patients it was home TPN (group C, n = 14). Complications were categorized into infectious complications and non-infectious complications, and related to patient characteristics, degree of immunosuppression, type of therapeutic medium, insertion technique and catheter survival time. Results: Type of complications could not be related to type of insertion procedure or length of operation, Catheter-related mortality was low in all groups (0-1%). Type of complications could be related to catheter survival time in all groups. Infectious complications could not be related to degree of immunosuppression (CD4+ lymphocyte counts or white blood cell count). Unexpectedly, the incidence of both infectious and non-infectious complications was significantly higher for group C than for groups A and B, probably because of type of medium and/or differences in handling of the catheter. Conclusion: In this retrospective study, central venous catheters appear to be safe and are well tolerated by AIDS patients, as compared to non-AIDS immunocompromised patients receiving chemotherapy and immunocompetent home-TPN patients.
AB - Objective: To investigate and compare the incidence and type of complications related to central venous catheters in AIDS patients and in two control groups of non-AIDS patients. Methods: Three groups of patients requiring permanent venous access were investigated retrospectively between January 1988 and January 1994, The indication for Port-A-Cath system implantation in AIDS patients was administration of virustatics and/or total parenteral nutrition (TPN) (group A, n = 71), in non-AIDS immunocompromised patients it was chemotherapy (group B, n = 65) and in immunocompetent patients it was home TPN (group C, n = 14). Complications were categorized into infectious complications and non-infectious complications, and related to patient characteristics, degree of immunosuppression, type of therapeutic medium, insertion technique and catheter survival time. Results: Type of complications could not be related to type of insertion procedure or length of operation, Catheter-related mortality was low in all groups (0-1%). Type of complications could be related to catheter survival time in all groups. Infectious complications could not be related to degree of immunosuppression (CD4+ lymphocyte counts or white blood cell count). Unexpectedly, the incidence of both infectious and non-infectious complications was significantly higher for group C than for groups A and B, probably because of type of medium and/or differences in handling of the catheter. Conclusion: In this retrospective study, central venous catheters appear to be safe and are well tolerated by AIDS patients, as compared to non-AIDS immunocompromised patients receiving chemotherapy and immunocompetent home-TPN patients.
KW - AIDS
KW - Central venous catheters
KW - Immunocompetent
KW - Immunocompromised
KW - Infectious complications
KW - Non-infectious complications
UR - http://www.scopus.com/inward/record.url?scp=0031668802&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/j.1469-0691.1998.tb00405.x
DO - https://doi.org/10.1111/j.1469-0691.1998.tb00405.x
M3 - Article
SN - 1469-0691
VL - 4
SP - 508
EP - 513
JO - Clinical Microbiological and Infection
JF - Clinical Microbiological and Infection
IS - 9
ER -